Together with the observations that Ad‐NR2F6‐injected mice exhibited more hepatic TG contents, these findings suggest that upregulation of NR2F6 represents a common feature of obesity‐related dyslipidemia and might be causally linked to the pathogenesis of NAFLD. This evidence concerns the gene NR2F6 and metabolic dysfunction-associated steatotic liver disease.